Microdosing Collective: Diamond Shruumz Recall ‘Tragically Highlights’ Risks of ‘Black-Market’ Psychedelics

MDMA for PTSD: Setback Sparks New Battle Plan

Myco Meditations Begins Rebuilding Effort After Hurricane Beryl

Johnson & Johnson Seeks FDA Approval of Spravato as Monotherapy for Adults with Treatment-Resistant Depression

NEWS

Lykos Therapeutics Shakeup Continues With Leadership Change

September 6, 2024

Lykos Therapeutics Slashes Workforce, Reshuffles Leadership After FDA Rejection

August 22, 2024

Cybin Holds ‘Productive’ Meeting with FDA to Discuss Plans for CYB003

August 21, 2024

Two Doctors Charged in Connection with Actor Matthew Perry’s Ketamine Overdose

August 16, 2024

MORE HEADLINES

Mr. Cannabis Law Rebrands as LumaLex Law, Expands Into Psychedelics

July 21, 2024

DEA: MIRA-55 Marijuana Analog Not a Controlled Substance

May 29, 2024

Psilocybin Spurs Dynamic Brain ‘Hyperconnectivity’ Linked to Psychedelic Epiphanies

May 24, 2024

OPINION

Guest Column: A Look at Jamaica’s Emerging Psilocybin Industry and the Path Forward

June 18, 2024

Guest Column: Can Psychedelics Revolutionize Chronic-Pain Treatment?

May 21, 2024

At-Home Ketamine Therapy: Breakthrough or Breakdown?

March 21, 2024

Navigating the Psychedelic Renaissance: The Intersection of Medicine, Spirituality and Big Business

January 3, 2024

Microdosing Collective: Diamond Shruumz Recall ‘Tragically Highlights’ Risks of ‘Black-Market’ Psychedelics

MDMA for PTSD: Setback Sparks New Battle Plan

Myco Meditations Begins Rebuilding Effort After Hurricane Beryl

Johnson & Johnson Seeks FDA Approval of Spravato as Monotherapy for Adults with Treatment-Resistant Depression

NEWS

Lykos Therapeutics Shakeup Continues With Leadership Change

Lykos Therapeutics Slashes Workforce, Reshuffles Leadership After FDA Rejection

Cybin Holds ‘Productive’ Meeting with FDA to Discuss Plans for CYB003

Two Doctors Charged in Connection with Actor Matthew Perry’s Ketamine Overdose

MORE HEADLINES

Mr. Cannabis Law Rebrands as LumaLex Law, Expands Into Psychedelics

DEA: MIRA-55 Marijuana Analog Not a Controlled Substance

Psilocybin Spurs Dynamic Brain ‘Hyperconnectivity’ Linked to Psychedelic Epiphanies

Guest Column: A Look at Jamaica’s Emerging Psilocybin Industry and the Path Forward

Guest Column: Can Psychedelics Revolutionize Chronic-Pain Treatment?

At-Home Ketamine Therapy: Breakthrough or Breakdown?

Navigating the Psychedelic Renaissance: The Intersection of Medicine, Spirituality and Big Business

Psilocybin

Microdosing Collective: Diamond Shruumz Recall ‘Tragically Highlights’ Risks of ‘Black-Market’ Psychedelics

Cybin Holds ‘Productive’ Meeting with FDA to Discuss Plans for CYB003

Myco Meditations Begins Rebuilding Effort After Hurricane Beryl

Ketamine

Two Doctors Charged in Connection with Actor Matthew Perry’s Ketamine Overdose

Johnson & Johnson Seeks FDA Approval of Spravato as Monotherapy for Adults with Treatment-Resistant Depression

NRx Pharmaceuticals to File Two New-Drug Applications in 2024

Ibogaine

Sergey Brin Invests in Ibogaine Start-Up

Massachusetts Psychedelic Legalization Initiative Advances to Ballot

Healing War Wounds: Stanford Explores Ibogaine’s Potential for Brain Injuries